3,787 Shares in AbbVie Inc. $ABBV Purchased by Puff Wealth Management LLC

Puff Wealth Management LLC purchased a new stake in shares of AbbVie Inc. (NYSE:ABBV) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 3,787 shares of the company’s stock, valued at approximately $953,000.

A number of other large investors also recently bought and sold shares of ABBV. Norges Bank purchased a new stake in AbbVie during the fourth quarter worth $5,865,055,000. Wellington Management Group LLP increased its holdings in AbbVie by 457.4% in the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after buying an additional 8,646,424 shares in the last quarter. Capital World Investors increased its holdings in AbbVie by 106.3% in the fourth quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock valued at $2,986,777,000 after buying an additional 6,736,161 shares in the last quarter. Cardano Risk Management B.V. raised its position in shares of AbbVie by 914.6% in the fourth quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company’s stock worth $1,244,112,000 after acquiring an additional 4,908,260 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of AbbVie by 10.4% in the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock worth $10,179,099,000 after acquiring an additional 4,190,487 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ABBV. Morgan Stanley restated an “overweight” rating and set a $296.00 target price on shares of AbbVie in a research report on Monday. Canaccord Genuity Group upped their price target on AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a report on Monday. Bank of America increased their price target on AbbVie from $234.00 to $276.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. HSBC reissued a “buy” rating and issued a $300.00 price objective on shares of AbbVie in a report on Monday, July 6th. Finally, Evercore set a $235.00 price objective on AbbVie in a research report on Friday, May 15th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $275.70.

AbbVie Stock Up 0.8%

Shares of ABBV opened at $245.82 on Friday. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47. The firm’s fifty day moving average is $241.96 and its two-hundred day moving average is $224.96. The stock has a market cap of $434.31 billion, a PE ratio of 69.44, a price-to-earnings-growth ratio of 0.81 and a beta of 0.30.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts anticipate that AbbVie Inc. will post 14.06 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. AbbVie’s dividend payout ratio is presently 195.48%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.